GlassScriptPhysician profile
Mona L Lane
NPI 1841258548
$9,973.10
in general payments reported to CMS, 2019-2025
53 companies · $1,065 in 2025
The $1,065 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,598 · 2020: $1,486 · 2021: $1,425 · 2022: $1,471 · 2023: $1,479 · 2024: $1,449 · 2025: $1,065.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,993.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,993.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,215.34 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,163.84 | 2019-2025 | Ubrelvy, Vraylar, Linzess |
| Astrazeneca Pharmaceuticals LP | $1,158.89 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $787.26 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Lilly USA, LLC | $723.53 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $594.14 | 2019-2024 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $397.20 | 2019-2024 | Trintellix |
| Pfizer INC. | $350.90 | 2020-2025 | |
| Amgen INC. | $263.04 | 2019-2025 | Repatha, Repatha, Otezla |
| Abbott Laboratories | $244.90 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Daiichi Sankyo INC. | $217.83 | 2019-2023 | Injectafer |
| Eisai INC. | $206.99 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $191.45 | 2022-2024 | Quviviq |
| Janssen Pharmaceuticals, INC | $184.94 | 2019-2023 | Xarelto |
| Allergan, INC. | $166.61 | 2019-2020 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mona Lane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.